A Case Report of Clobazam Toxicity Related to Cannabidiol and Clobazam Drug-drug Interaction

Authors

  • Rowida Kheireldin

DOI:

https://doi.org/10.46570/utjms.vol6-2019-339

Keywords:

Epidiolex, Clobazam, Dravet syndrome, LennoxGastuat syndrome

Abstract

The interest in the anti-seizure efficacy of cannabinoids (CBD)has significantly increased over the past decade. Trials have shown a remarkable reduction in the frequency of convulsive seizures in Dravet and Lennox-Gastaut syndromes patient population. Studies have shown that CBD reacts with Clobazam leading to a significant increase in the levels of N-desmethylclobazam, the active metabolite of Clobazam. We present a case of a patient with Dravet syndrome who presented to the emergency department with altered mental status secondary to Clobazam toxicity related to CBD and Clobazam drug-drug interaction. We present a case of a patient with Dravet syndrome who presented to the emergency department with altered mental status. Patient was hospitalized and Clobazam was held off. Clobazam level and N-desmethylclobazam levels were obtained and came back elevated at 512 ng/mL and 15020 ng/mL respectively (reference range 30-300 ng/mL and 300 to 3000 ng/mL respectively).

Rowida Kheireldin (a) (1) Naeem Mahfooz (b)

References

Footnotes included in the article

Downloads

Published

2019-12-03

How to Cite

Kheireldin, R. (2019). A Case Report of Clobazam Toxicity Related to Cannabidiol and Clobazam Drug-drug Interaction. Translation: The University of Toledo Journal of Medical Sciences, 6, 35–36. https://doi.org/10.46570/utjms.vol6-2019-339

Issue

Section

Case Reports